Profile data is unavailable for this security.
About the company
Citius Pharmaceuticals, Inc. is a late-stage biopharmaceutical company. It develops and commercializes critical care products with a focus on oncology, anti-infectives in adjunct cancer care, prescription products and stem cell therapy. Its products include LYMPHIR, Mino-Lok, Halo-Lido, NoveCite and Mino-Wrap. LYMPHIR is an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma. Mino-Lok is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections by salvaging the infected catheter. Halo-Lido is a corticosteroid-lidocaine topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids. Mino-Wrap is a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries. NoveCite is a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome.
- Revenue in USD (TTM)0.00
- Net income in USD-39.77m
- Incorporated2010
- Employees22.00
- LocationCitius Pharmaceuticals Inc11 Commerce Dr Fl 1CRANFORD 07016-3501United StatesUSA
- Phone+1 (908) 967-6677
- Websitehttps://www.citiuspharma.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Rapt Therapeutics Inc | 0.00 | -120.43m | 65.62m | 122.00 | -- | 0.6008 | -- | -- | -3.12 | -3.12 | 0.00 | 3.13 | 0.00 | -- | -- | 0.00 | -69.23 | -46.30 | -75.81 | -49.97 | -- | -- | -- | -3,522.72 | -- | -- | 0.00 | -- | -100.00 | -- | -39.31 | -- | -20.31 | -- |
Precision BioSciences Inc | 87.64m | 15.79m | 66.19m | 110.00 | -- | 0.8724 | 3.16 | 0.7552 | -0.1363 | 0.202 | 17.59 | 10.49 | 0.5044 | -- | 79.03 | 804,036.70 | 9.09 | -35.35 | 12.24 | -44.22 | -- | -- | 18.02 | -147.50 | -- | -- | 0.2314 | -- | 94.15 | 34.96 | 41.67 | -- | -32.01 | -- |
Spero Therapeutics Inc | 118.46m | 17.46m | 67.02m | 46.00 | 3.91 | 0.8319 | 3.80 | 0.5658 | 0.3169 | 0.3169 | 2.21 | 1.49 | 0.9524 | -- | 4.11 | 2,575,196.00 | 14.03 | -35.52 | 18.79 | -41.75 | -- | -- | 14.74 | -124.40 | -- | -- | 0.00 | -- | 93.95 | 92.11 | 149.14 | -- | -- | -- |
Boundless Bio Inc | 0.00 | -57.72m | 67.88m | 72.00 | -- | 0.3787 | -- | -- | -2.60 | -2.60 | 0.00 | 8.05 | 0.00 | -- | -- | 0.00 | -33.64 | -- | -35.41 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -7.70 | -- | -- | -- |
Citius Pharmaceuticals Inc | 0.00 | -39.77m | 70.19m | 22.00 | -- | 0.8192 | -- | -- | -0.2443 | -0.2443 | 0.00 | 0.4741 | 0.00 | -- | -- | 0.00 | -36.91 | -30.26 | -39.00 | -32.11 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -0.1589 | -- | -- | -- |
Connect Biopharma Holdings Ltd (ADR) | 24.12m | -21.25m | 70.73m | 81.00 | -- | 0.6402 | -- | 2.93 | -0.3869 | -0.3869 | 0.436 | 2.00 | 0.1826 | -- | -- | 297,728.40 | -16.09 | -66.24 | -17.73 | -71.36 | -- | -- | -88.10 | -- | -- | -- | 0.0029 | -- | -- | -- | 49.61 | -- | 10.32 | -- |
Immuneering Corp | 0.00 | -56.07m | 70.87m | 66.00 | -- | 1.07 | -- | -- | -1.91 | -1.91 | 0.00 | 2.24 | 0.00 | -- | -- | 0.00 | -55.52 | -- | -59.10 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -100.00 | -- | -5.86 | -- | -- | -- |
VolitionRX Ltd | 976.52k | -32.42m | 71.18m | 110.00 | -- | -- | -- | 72.89 | -0.4032 | -0.4032 | 0.0121 | -0.263 | 0.0481 | -- | 5.38 | 8,877.45 | -161.39 | -111.92 | -- | -196.20 | -- | -- | -3,357.34 | -10,793.31 | -- | -129.66 | -- | -- | 153.04 | -- | -16.68 | -- | 29.13 | -- |
Adlai Nortye Ltd (ADR) | 5.00m | -54.07m | 72.69m | 127.00 | -- | 1.36 | -- | 14.54 | -6.21 | -6.21 | 0.2465 | 1.45 | -- | -- | -- | 39,370.08 | -- | -- | -- | -- | -- | -- | -1,081.30 | -- | -- | -- | 0.4255 | -- | -- | -- | -78.38 | -- | -- | -- |
Citius Oncology Inc | 0.00 | 1.93m | 73.44m | -- | 4.26 | 0.1486 | 37.98 | -- | 0.242 | 0.242 | 0.00 | 6.93 | 0.00 | -- | -- | -- | 3.25 | -- | 3.35 | -- | -- | -- | -- | -- | -- | -- | 0.036 | -- | -- | -- | 535.30 | -- | -- | -- |
Cue Biopharma Inc | 8.30m | -46.96m | 74.06m | 53.00 | -- | 2.77 | -- | 8.93 | -0.9743 | -0.9743 | 0.1718 | 0.4445 | 0.1437 | -- | 5.56 | 156,528.30 | -81.32 | -57.45 | -113.52 | -68.41 | -- | -- | -566.02 | -810.87 | -- | -- | 0.2242 | -- | 340.88 | 36.88 | 4.30 | -- | -- | -- |
Aileron Therapeutics Inc | 0.00 | -25.22m | 74.53m | 15.00 | -- | 1.33 | -- | -- | -3.25 | -3.25 | 0.00 | 4.67 | 0.00 | -- | -- | 0.00 | -40.88 | -65.99 | -43.02 | -75.37 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 42.43 | -- | -- | -- |
Metagenomi Inc | 55.93m | -75.00m | 75.30m | 228.00 | -- | 0.2795 | -- | 1.35 | -2.53 | -2.53 | 1.68 | 7.19 | 0.1408 | -- | 28.13 | 236,987.30 | -18.88 | -- | -22.14 | -- | -- | -- | -134.10 | -- | -- | -- | 0.00 | -- | 160.21 | -- | -56.57 | -- | -- | -- |
Cidara Therapeutics Inc | 31.58m | -116.17m | 75.38m | 69.00 | -- | 0.3737 | -- | 2.39 | -25.49 | -25.30 | 6.95 | 28.66 | 0.2617 | -- | 8.06 | 457,623.20 | -96.27 | -65.23 | -136.45 | -154.37 | 91.14 | -- | -367.91 | -100.61 | -- | -- | 0.0053 | -- | -0.8425 | -- | 31.72 | -- | 23.33 | -- |
Holder | Shares | % Held |
---|---|---|
BlackRock Fund Advisorsas of 31 Mar 2024 | 8.12m | 4.49% |
The Vanguard Group, Inc.as of 31 Mar 2024 | 6.89m | 3.81% |
SSgA Funds Management, Inc.as of 31 Mar 2024 | 2.21m | 1.22% |
Geode Capital Management LLCas of 30 Jun 2024 | 1.65m | 0.91% |
Northern Trust Investments, Inc.(Investment Management)as of 31 Mar 2024 | 1.12m | 0.62% |
American Portfolios Advisors, Inc.as of 31 Mar 2024 | 895.55k | 0.50% |
Charles Schwab Investment Management, Inc.as of 31 Mar 2024 | 356.99k | 0.20% |
BlackRock Investment Management LLCas of 31 Mar 2024 | 334.13k | 0.19% |
BlackRock Advisors LLCas of 31 Mar 2024 | 227.43k | 0.13% |
Hightower Advisors LLCas of 31 Mar 2024 | 209.86k | 0.12% |